Treatment with extended release naltrexone/bupropion (NB) for weight loss significantly improved and normalized serum ALT levels in obese and overweight individuals at high risk for non-alcoholic fatty liver disease (NAFLD) with elevated liver enzymes, reported Allison Winokur, PhD, from Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, at The Liver Meeting® 2015.
Treatment with tenofovir disoproxil fumarate in late pregnancy in highly viremic mothers with hepatitis B virus (HBV) infection effectively reduced mother-to-child transmission, a study reported at The Liver Meeting® 2015.
Adult doses of sofosbuvir plus ribavirin or ledipasvir/sofosbuvir provided comparable plasma exposures and tolerable safety profile in adolescents with hepatitis C virus (HCV) infection, reported Brian Kirby, PhD, from Gilead Sciences, Foster City, CA, at The Liver Meeting® 2015.
Monotherapy with tenofovir disoproxil fumarate (TDF) was equally effective as combination therapy with emtricitabine/TDF (FTC/TDF) in patients with chronic hepatitis B virus (HBV) infection harboring lamivudine resistance mutations, a study presented at The Liver Meeting® 2015 has found.
Antiviral therapy in patients with non-cirrhotic chronic hepatitis B (CHB) and normal to minimally-elevated alanine aminotransferase (ALT) levels significantly reduced the risk of hepatocellular carcinoma, reported Joseph K. Hoang from Stanford University Medical Center, Palo Alto, CA, at The Liver Meeting® 2015.
A rapid decline in serum/plasma lysyl oxidase-like-2 (LOXL2) levels was seen in cirrhotic patients treated with sofosbuvir (SOF)-based therapy, reported authors of a new study presented at The Liver Meting® 2015.
Statin use and liver cancer were independently associated with older age, race, higher prevalence of diabetes, liver cirrhosis, smoking, BMI, and more total healthcare utilization, a study reported at The Liver Meeting® 2015.
The benefits of eradicating hepatitis C virus (HCV) infection with sofosbuvir may go well beyond avoiding the damage caused by chronic liver inflammation, to include declines in glycated hemoglobin (HbA1c) and other metabolic parameters, according to a study reported at The Liver Meeting® 2015.
Combination treatment with peginterferon alfa-2a (peg-IFN) and adefovir or tenofovir for 48 weeks results in a loss and greater decline in HBsAg compared to no treatment in chronic hepatitis B (CHB) patients with a low viral load (LVL), reported Annikki de Niet, MD, from Academic Medical Center, Amsterdam, Netherlands, at The Liver Meeting® 2015.
New data reported at The Liver Meeting® 2015 indicate that entecavir monotherapy without hepatitis B immune globulin (HBIG) effectively prevents graft loss and death from recurrent hepatitis B after liver transplantation in patients with chronic hepatitis B without prior drug resistant mutations.
Drinking coffee might reduce the risk of alcoholic hepatitis (AH) among heavy alcohol drinkers, according to a study reported at The Liver Meeting® 2015
Peginterferon alfa-2b (Pegberon) demonstrates non-inferior efficacy to peginterferon alfa-2a (PEG IFNα-2a) for the treatment of Chinese HBeAg-positive chronic hepatitis B (CHB) patients, reported Gui-Qiang Wang, MD, PhD, from Peking University First Hospital, Beijing, China, at The Liver Meeting® 2015.
Early biomarkers cystatin C and NGAL may facilitate the safe delivery of long-term nucleos(t)ide analogue (NA) therapy for patients who have undergone liver transplantation, according to a study reported at the The Liver Meeting® 2015.
Aspirin and clopidogrel therapy are associated with reduced risk of hepatocellular carcinoma (HCC) among patients with chronic hepatitis B infection, according to a study reported at the The Liver Meeting® 2015.
The combination of two next-generation direct-acting antiviral (DAA) agents, ABT-493 and ABT-530, was "well tolerated," with all non-cirrhotic patients with hepatitis C virus (HCV) genotype 1 (GT1) infection who completed the 8-week treatment period achieving sustained virologic response at 12 weeks (SVR12), a study presented at The Liver Meeting 2015® has found.
In patients with minimal hepatic encephalopathy, nutritional therapy is effective and improves HRQOL, a randomized controlled trial presented during The Liver Meeting® 2015 has reported.
Portal vein thrombosis, a complication of cirrhosis, has an annual incidence of 4% in Spain, with risk factors being use of beta-blockers and hepatic encephalopsy, investigators reported during The Liver Meeting® 2015.
Oral combination sofosbuvir (SOF) and ribavirin (RBV) therapy is "efficacious and well-tolerated" among patients with hepatitis C virus (HCV) genotype 2 or genotype 3 infection, confirmed authors of a study presented at the The Liver Meeting® 2015.
Patients with chronic hepatitis B virus (HBV) treated with tenofovir rescue monotherapy achieve antiviral efficacy rates similar to those of tenofovir-based combination rescue therapy, even in patients with multi-drug resistance, investigators reported during The Liver Meeting® 2015.
Mild or moderate renal impairment did not impact direct-acting antivirals (DAA) and ritonavir (RTV) exposures, a study presented at The Liver Meeting® 2015 found.
Interferon-free ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin showed a more favorable Work Productivity and Activity Impairment (WPAI) profile in treatment-naïve, non-cirrhotic, HCV GT1-infected patients vs. telaprevir + peginterferon/ribavirin (TPV + pegIFN/RBV), reported Yan Liu, MD, PhD, from AbbVie, North Chicago, IL at The Liver Meeting® 2015.
At The Liver Meeting® 2015, researchers reported that the efficacy of dual oral therapy with asunaprevir + daclatasvir was comparable between elderly and non-elderly patients with chronic hepatitis C, including compensated cirrhosis.
Tania M. Welzel, MD, of the Department of Medicine, JW Goethe University Hospital in Frankfurt am Main, Germany, reported, "Among liver transplant recipients treated with LDV/SOF + RBV, similar rapid declines in HCV RNA were observed irrespective of whether patients received CyA or TAC for immunosuppression," at The Liver Meeting® 2015.
When all patients with hepatitis C virus (HCV) with genotype 3 (GT3) infection are treated with daclatasvir/sofosbuvir, substantially fewer medical events and lower medical costs are accrued" vs. scenarios in which no one is treated or treatment is limited to F3/F4 patients, results of a study using a Markov model presented at The Liver Meeting® 2015 concluded.
Partial virological response to entecavir does not affect long-term clinical outcome in patients with chronic hepatitis B virus (HBV) infection, according to a study presented at The Liver Meeting® 2015.
Ledipasvir/sofosbuvir given once daily for 12 weeks was highly effective in Asian patients with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection, including those with compensated cirrhosis, a study concluded at The Liver Meeting® 2015.
Patients with recurrent hepatitis C virus (HCV) genotype 1 (GT1) infection treated with the "3D+R" regimen post-transplant have a substantially lower likelihood of experiencing compensated or decompensated cirrhosis and death compared with the standard of care, 48 weeks of pegylated interferon plus ribavirin, or no treatment, a study reported at The Liver Meeting® 2015.
Biologic agents are associated with "significantly higher" risk of hepatitis B virus (HBV) flares than non-biologic disease-modifying antirheumatic drugs (nbDMARDs) among patients with rheumatoid arthritis (RA) or psoriasis, according to a study reported at The Liver Meeting® 2015.
In patients with minimal hepatic encephalopathy, prophylactic lactulose treatment improves cognition, quality of life, and intestinal microbiota, results of a multicenter, randomized, controlled trial presented at The Liver Meeting® 2015 have shown.
Ledipasvir/sofosbuvir with ribavirin treatment for 12 or 24 weeks in patients with decompensated cirrhosis or recurrent hepatitis C virus (HCV) was effective, with low relapse rates, Edward J. Gane, MBChB, MD, from the University of Auckland, Auckland, New Zealand, presented at The Liver Meeting® 2015.